We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Covis currently sells Alvesco, Omnaris and Zetonna in the US and will become the owner of the medicines. In return, it will pay AstraZeneca $350 million upon closing.
Sunovion has entered into a definitive agreement to divest the U.S. market rights to Sunovion’s ciclesonide products ALVESCO Inhalation Aerosol, OMNARIS Nasal Spray, and ZETONNA Nasal Aerosol to Covis Pharma. Ciclesonides are included in the corticosteroi